Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 43 results
Filters: First Letter Of Title is H  [Clear All Filters]
Found 43 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Matoga MM, Hosseinipour MC, Aga E, et al. "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings." Antivir. Ther. (Lond.). 2016.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. "Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230." Open Forum Infect Dis. 2016;3(3):ofw154.
Haas DW. "Human genetic variability and HIV treatment response." Curr HIV/AIDS Rep. 2006;3(2):53-8.
Funderburg N, Lederman MM, Feng Z, et al. "Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2." Proc. Natl. Acad. Sci. U.S.A.. 2007;104(47):18631-5.
Lee SA, Mefford JA, Huang Y, et al. "Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans." AIDS. 2016;30(11):1807-15.
Hubbard JJ, Greenwell-Wild T, Barrett L, et al. "Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a." J. Infect. Dis.. 2012;205(9):1443-7.
Imamichi H, Degray G, Asmuth DM, et al. "HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy." AIDS. 2011;25(2):159-64.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Rhee S-Y, Kantor R, Katzenstein DA, et al. "HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes." AIDS. 2006;20(5):643-51.
Mitsuya Y, Winters MA, W Fessel J, et al. "HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL." J. Acquir. Immune Defic. Syndr.. 2006;43(1):56-9.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Rockwood N, Meintjes G, Chirehwa M, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrob. Agents Chemother.. 2016;60(10):6050-9.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Simpson DM, Kitch D, Evans SR, et al. "HIV neuropathy natural history cohort study: assessment measures and risk factors." Neurology. 2006;66(11):1679-87.
Bronke C, Almeida C-AM, McKinnon E, et al. "HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes." AIDS. 2013;27(6):899-905.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Yonkers NL, Rodriguez B, Post AB, et al. "HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells." J. Infect. Dis.. 2006;194(3):391-400.
Shah, iv S, Mildvan D. "HIV and aging." Curr Infect Dis Rep. 2006;8(3):241-7.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Wilkin T, Lee JY, Lensing SY, et al. "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine." HIV Clin Trials. 2013;14(2):75-9.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.

Pages